{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460037234
| IUPAC_name = 6-[4-(1-Cyclohexyl-1''H''-tetrazol-5-yl)butoxy]-<br>3,4-dihydro-2(1''H'')-quinolinone
| image = Cilostazol.svg
| width = 250

<!--Clinical data-->
| pronounce = {{IPAc-en|s|ᵻ|ˈ|l|ɒ|s|t|ə|z|ɒ|l}}<br />{{respell|sil|OS|tə-zol}}
| tradename = Pletaal
| Drugs.com = {{drugs.com|monograph|cilostazol}}
| MedlinePlus = a601038
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = [[口服给药|口服给药]]（[[片剂|藥丸]]）

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 95–98%
| metabolism = [[肝臟|肝臟]]（經由[[CYP3A4|CYP3A4]]和[[CYP2C19|CYP2C19]]代謝） (- and -mediated)
| elimination_half-life = 11–13 小時
| excretion = [[腎|腎]]

<!--Identifiers-->
| IUPHAR_ligand = 7148
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 73963-72-1
| ATC_prefix = B01
| ATC_suffix = AC23
| PubChem = 2754
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01166
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2652
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N7Z035406B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01896
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31401
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 799

<!--Chemical data-->
| C=20 | H=27 | N=5 | O=2
| molecular_weight = 369.46 g/mol
| smiles = O=C4Nc3c(cc(OCCCCc1nnnn1C2CCCCC2)cc3)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RRGUKTPIGVIEKM-UHFFFAOYSA-N
}}

'''西洛他唑'''（Cilostazol）為一種[[喹啉|喹啉]]衍生類藥物，可用於緩解[[周邊動脈阻塞|周邊動脈阻塞]]患者的{{tsl|en|intermittent claudication|間歇性跛行}}的症狀。本品的製造商為[[大塚製藥|大塚製藥]]，以商品名'''普達錠'''（Pletaal）販售。相對於其他類似物常造成[[心臟衰竭|鬱血性心衰竭]]患者死亡率提升，本品並不會導致類似的副作用。本品屬於[[磷酸二酯酶抑制药|磷酸二酯酶抑制药]]，可使[[环腺苷酸|环腺苷酸]]（cAMP）的濃度上升。本品可抑制血小板聚集，且可直接造成血管擴張。

==機轉==
本品屬於選擇性{{tsl|en|Phosphodiesterase 3|磷酸二酯酶3}}抑制劑，使cAMP的量增加。當cAMP增加之後，[[蛋白激酶A|蛋白激酶A]]（PKA）轉為活化態的比例會提升，進而抑制血小板的凝集。PKA同時也可以預防[[肌球蛋白輕鏈激酶|肌球蛋白輕鏈激酶]]的活化，抑制平滑肌的收縮，使血管能夠擴張。

==參考文獻==
{{Reflist}}

==外部連結==
* [http://www.drugdigest.org/DD/DVH/Uses/0,3915,733|Pletal,00.html Supplementary information provided by Drug Digest] (Link not working 2/8/12)
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Cilostazol U.S. National Library of Medicine: Drug Information Portal - Cilostazol]
{{Clear}}
{{Antithrombotics}}
{{Purinergics}}

[[Category:抗血小板药|Category:抗血小板药]]
[[Category:血管扩张剂|Category:血管扩张剂]]
[[Category:四唑|Category:四唑]]
[[Category:芳香醚|Category:芳香醚]]